• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Distinct immune response to CoronaVac in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic disease.

作者信息

Gao Xing-Su, Zhu Feng-Cai

机构信息

Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China.

NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.

出版信息

Lancet Rheumatol. 2022 Feb;4(2):e77-e78. doi: 10.1016/S2665-9913(21)00392-1. Epub 2021 Dec 3.

DOI:10.1016/S2665-9913(21)00392-1
PMID:34901883
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8641957/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2145/8641957/bedac20ec3c9/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2145/8641957/bedac20ec3c9/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2145/8641957/bedac20ec3c9/fx1_lrg.jpg

相似文献

1
Distinct immune response to CoronaVac in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic disease.新冠病毒血清阳性和血清阴性的自身免疫性风湿病患者对科兴新冠疫苗的不同免疫反应。
Lancet Rheumatol. 2022 Feb;4(2):e77-e78. doi: 10.1016/S2665-9913(21)00392-1. Epub 2021 Dec 3.
2
Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series.在系统性红斑狼疮患者中使用异源加强针后，康希诺新冠疫苗的免疫原性、安全性和反应原性：一项病例系列研究。
RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-002019.
3
Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals.在血清阳性和血清阴性个体中接种 SARS-CoV-2 mRNA 疫苗期间的体液免疫反应。
BMC Med. 2021 Jul 26;19(1):169. doi: 10.1186/s12916-021-02055-9.
4
SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study.SARS-CoV-2 血清阳性率及健康青年随后的感染风险：一项前瞻性队列研究。
Lancet Respir Med. 2021 Jul;9(7):712-720. doi: 10.1016/S2213-2600(21)00158-2. Epub 2021 Apr 15.
5
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children.在无意中接种了 SARS-CoV-2 灭活疫苗（科兴疫苗）的健康儿童中的安全性和免疫原性。
Rev Inst Med Trop Sao Paulo. 2021 Dec 6;63:e83. doi: 10.1590/S1678-9946202163083. eCollection 2021.
6
Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.CoronaVac 疫苗诱导的抗体对 alpha、gamma 和 D614G SARS-CoV-2 变异株的中和作用。
J Med Virol. 2022 Jan;94(1):399-403. doi: 10.1002/jmv.27310. Epub 2021 Sep 8.
7
SARS-CoV-2 Infection and Antibody Seroprevalence among UK Healthcare Professionals Working with Cancer Patients during the First Wave of the COVID-19 Pandemic.SARS-CoV-2 感染和抗体血清阳性率在英国医疗保健专业人员中与癌症患者合作在 COVID-19 大流行的第一波期间。
Clin Oncol (R Coll Radiol). 2021 Oct;33(10):667-675. doi: 10.1016/j.clon.2021.04.005. Epub 2021 Apr 24.
8
Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology.恢复期 COVID-19 患者中 SARS-CoV-2 抗体血清学阴性的反应性 T 细胞。
Front Immunol. 2021 Jul 12;12:687449. doi: 10.3389/fimmu.2021.687449. eCollection 2021.
9
Risk Factors for Being Seronegative following SARS-CoV-2 Infection in a Large Cohort of Health Care Workers in Denmark.丹麦大型医护人员队列中 SARS-CoV-2 感染后血清阴性的危险因素。
Microbiol Spectr. 2021 Oct 31;9(2):e0090421. doi: 10.1128/Spectrum.00904-21. Epub 2021 Oct 20.
10
Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy.母体接种 SARS-CoV-2 灭活疫苗（科兴）后脐带血抗体。
Hum Vaccin Immunother. 2021 Oct 3;17(10):3484-3486. doi: 10.1080/21645515.2021.1947099. Epub 2021 Jul 30.

引用本文的文献

1
Coronavirus disease 2019 vaccination uptake and hesitancy among Polish patients with inborn errors of immunity, autoinflammatory syndromes, and rheumatic diseases: A multicenter survey.2019 年冠状病毒病疫苗接种情况及波兰遗传性免疫缺陷、自身炎症性疾病和风湿性疾病患者的犹豫：一项多中心调查。
Front Immunol. 2022 Oct 6;13:1010899. doi: 10.3389/fimmu.2022.1010899. eCollection 2022.
2
Immunogenicity of Inactivated SARS-CoV-2 Vaccines in Patients With Rheumatoid Arthritis: A Case Series.类风湿关节炎患者接种灭活 SARS-CoV-2 疫苗的免疫原性：病例系列研究。
Front Public Health. 2022 Apr 25;10:875558. doi: 10.3389/fpubh.2022.875558. eCollection 2022.

本文引用的文献

1
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study.两剂科兴新冠病毒疫苗在巴西自身免疫性风湿病血清阳性和血清阴性患者中的免疫原性和安全性：一项4期前瞻性研究的亚组分析
Lancet Rheumatol. 2022 Feb;4(2):e113-e124. doi: 10.1016/S2665-9913(21)00327-1. Epub 2021 Dec 3.
2
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies.荷兰自身免疫性疾病患者接种新冠疫苗后的抗体产生情况：两项前瞻性队列研究数据的子研究
Lancet Rheumatol. 2021 Nov;3(11):e778-e788. doi: 10.1016/S2665-9913(21)00222-8. Epub 2021 Aug 6.
3
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.CoronaVac 灭活疫苗在自身免疫性风湿病患者中的免疫原性和安全性：一项 4 期临床试验。
Nat Med. 2021 Oct;27(10):1744-1751. doi: 10.1038/s41591-021-01469-5. Epub 2021 Jul 30.
4
Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination.mRNA 疫苗接种后 SARS-CoV-2 初免者和康复者的抗体和记忆 B 细胞反应存在差异。
Sci Immunol. 2021 Apr 15;6(58). doi: 10.1126/sciimmunol.abi6950.
5
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.先前感染过 SARS-CoV-2 的个体对 BNT162b2 mRNA 疫苗的抗体反应。
Nat Med. 2021 Jun;27(6):981-984. doi: 10.1038/s41591-021-01325-6. Epub 2021 Apr 1.
6
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.单剂 SARS-CoV-2 mRNA 疫苗接种后血清阳性者的抗体反应。
N Engl J Med. 2021 Apr 8;384(14):1372-1374. doi: 10.1056/NEJMc2101667. Epub 2021 Mar 10.